BGC0222 is a novel prodrug of Irinotecan (HY-16562). BGC0222, as a PEG-cRGD-conjugated Irinotecan (HY-16562) derivative, could slowly and steadily release Irinotecan (HY-16562). BGC0222 binds to alphaVbeta3 with IC50 values of 4.25 µM (alphaVbeta3) and 58.7 µM (alphaVbeta5). BGC0222 possesses the property of inducing neovascularization. BGC0222 exhibits good antiproliferation activity in many tumors[1].
Molecular Weight:
26927.36
Formula:
C1241H2276N64O552
Target:
Integrin,Peptide-Drug Conjugates (PDCs)
Application Notes:
Peptides
* VAT and and shipping costs not included. Errors and price changes excepted
